PT-141 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
| Property | Value | Notes |
|---|---|---|
| Solubility class | Freely soluble in water | Also soluble in DMSO and some alcohols |
| Typical storage temperature | -20 C or below | Desiccated, protected from light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
| Typical reported purity | 95 percent or higher | Reference-grade material |
| Common synonyms | PT-141 | Also called bremelanotide acetate |
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
== Properties == Bromine is the third halogen, being a nonmetal in group 17 of the periodic table. Its properties are thus similar to those of fluorine, chlorine, and iodine, and tend to be intermediate between those of chlorine and iodine, the two neighbouring halogens. Bromine has the electron configuration [Ar]4s23d104p5, with the seven electrons in the fourth and outermost shell acting as its valence electrons. Like all halogens, it is thus one electron short of a full octet, and is hence a strong oxidising agent, reacting with many elements in order to complete its outer shell. Corresponding to periodic trends, it is intermediate in electronegativity between chlorine and iodine (F: 3.98, Cl: 3.16, Br: 2.96, I: 2.66), and is less reactive than chlorine and more reactive than iodine. It is also a weaker oxidising agent than chlorine, but a stronger one than iodine. Conversely, the bromide ion is a weaker reducing agent than iodide, but a stronger one than chloride. These similarities led to chlorine, bromine, and iodine together being classified as one of the original triads of Johann Wolfgang Döbereiner, whose work foreshadowed the periodic law for chemical elements. It is intermediate in atomic radius between chlorine and iodine, and this leads to many of its atomic properties being similarly intermediate in value between chlorine and iodine, such as first ionisation energy, electron affinity, enthalpy of dissociation of the X2 molecule (X = Cl, Br, I), ionic radius, and X–X bond length.
== Career == After obtaining his undergraduate degrees, Wood started working on high-viscosity mucopolysaccharide fermentation development at CP Kelco in San Diego, California. Soon after, he joined Amgen in 1991, the same year that Amgen received FDA approval for Neupogen. This recombinant protein cytokine drug induces white blood cell production to fight infections in immunocompromised cancer patients after undergoing chemotherapy or radiation treatment. Wood worked on the GMP fermentation team to manufacture Neupogen (rhG-CSF) between 1991 and 1993. Neupogen became one of the most successful biotech drugs at that time and second blockbuster for Amgen after Epogen. In 1993, Wood joined the group of Georges Belfort as a Ph.D. student at Rensselaer Polytechnic Institute, where he worked primarily on mini-intein development for protein purification. During this time, he engineered the ∆I-CM intein, which was derived from Mycobacterium tuberculosis recA intein. After earning his Ph.D. he joined a team at Bristol Myers Squibb in Hopewell, New Jersey. This time he focused on the recovery and in vitro processing of transgenic monoclonal antibody therapeutics. In 2001, Wood started his academic career at Princeton University as an assistant professor of chemical and biological engineering, where he continued his research focusing on self-removing tags, protein engineering, and applied biosensors. In 2009, he joined the Chemical and Biomolecular Engineering Department at Ohio State University as an associate professor and soon after was appointed as a full professor.
Partition coefficients can also be defined when one of the phases is solid, for instance, when one phase is a molten metal and the second is a solid metal, or when both phases are solids. The partitioning of a substance into a solid results in a solid solution. Partition coefficients can be measured experimentally in various ways (by shake-flask, HPLC, etc.) or estimated by calculation based on a variety of methods (fragment-based, atom-based, etc.). If a substance is present as several chemical species in the partition system due to association or dissociation, each species is assigned its own Kow value. A related value, D, does not distinguish between different species, only indicating the concentration ratio of the substance between the two phases.
Sources: en.wikipedia.org
An expression vector must have elements necessary for gene expression. These may include a promoter, the correct translation initiation sequence such as a ribosomal binding site and start codon, a termination codon, and a transcription termination sequence. There are differences in the machinery for protein synthesis between prokaryotes and eukaryotes, therefore the expression vectors must have the elements for expression that are appropriate for the chosen host. For example, prokaryotes expression vectors would have a Shine-Dalgarno sequence at its translation initiation site for the binding of ribosomes, while eukaryotes expression vectors would contain the Kozak consensus sequence. The promoter initiates the transcription and is therefore the point of control for the expression of the cloned gene. The promoters used in expression vector are normally inducible, meaning that protein synthesis is only initiated when required by the introduction of an inducer such as IPTG. Gene expression however may also be constitutive (i.e. protein is constantly expressed) in some expression vectors. Low level of constitutive protein synthesis may occur even in expression vectors with tightly controlled promoters.
Patients who do not drink may require fluids by nasogastric tube. Intravenous fluids are recommended only in those who have significant dehydration due to their potential complications, including congestive heart failure.
A record in the form of proof of baptisms shall be made, containing the time and hour of birth. An extract from this register may be used to prove the age of majority or minority and will serve as full legal evidence for this purpose. Before this legal requirement, fifteen Parisian parishes already kept baptismal registers, three kept marriage registers, and one kept burial registers. Presided over by Pope Paul III from 1545 to 1563, the Council of Trent also required priests to keep a register of baptisms performed in their parish. The names of godparents had to be included to prevent marriages between people linked by spiritual kinship (e.g., a godfather and his goddaughter could not marry). The council also mandated that marriages, freely contracted before a priest and two or three witnesses, be preceded by the publication of banns and recorded in a designated register. It also advocated for the union of children without requiring parental consent. In May 1579, the Ordinance of Blois extended the obligation to keep marriage and burial registers throughout France. The Ordinance of Saint-Germain-en-Laye of April 1667, known as the "Code Louis," required these registers to be kept in duplicate: the first copy (the minute) remained in the parish, while the duplicate (the grosse) was deposited at the court registry. In Paris, the Châtelet registry preserved the second copy, with the oldest dating back to 1668. By 1790, the capital had around fifty parishes.
Sulfate uptake occurs in roots. The maximal sulfate uptake rate is generally already reached at sulfate levels of 0.1 mM and lower. The uptake of sulfate by the roots and its transport to the shoot appears to be one of the primary regulatory sites of sulfur assimilation. Sulfate is actively taken up across the plasma membrane of the root cells, subsequently loaded into the xylem vessels and transported to the shoot by the transpiration stream. The uptake and transport of sulfate is ATP-dependent. Sulfate is reduced in the chloroplasts. Sulfate in plant tissue is predominantly present in the vacuole, since the concentration of sulfate in the cytoplasm is kept rather constant. Distinct sulfate transporter proteins mediate the uptake, transport and subcellular distribution of sulfate. The sulfate transporters gene family has been classified in up to 5 different groups according to their cellular and sub-cellular gene expression, and possible functioning. Each group of transporter proteins may be expressed exclusively in the roots or shoots of the plant, or both.
Sources: en.wikipedia.org
== History == DART resulted from conversations between Laramee and Cody about the development of an atmospheric pressure ion source to replace the radioactive sources in handheld chemical weapons detectors. DART was developed in late 2002 to early 2003 by Cody and Laramee as a new atmospheric pressure ionization process, and a US patent application was filed in April 2003. Although the development of DART actually predated the desorption electrospray ionization (DESI) ion source, the initial DART publication did not appear until shortly after the DESI publication, and both ion sources were publicly introduced in back-to-back presentations by R. G. Cooks and R. B. Cody at the January 2005 ASMS Sanibel Conference. DESI and DART are considered as pioneer techniques in the field of ambient ionization, since they operate in the open laboratory environment and do not require sample pretreatment. In contrast to the liquid spray used by DESI, the ionizing gas from the DART ion source contains a dry stream containing excited state species.
=== Interactions === If people are using sNRI drugs they should not take MAO inhibitors at the same time. That can increase the plasma concentration of NRIs in the body. Beware of taking atomoxetine in combination with:
Imogen Heap – vocals, production, mixing, engineering, programming Ashwin Srinivasan – background vocals (track 6), flute (track 6) Leo Abrahams – electric guitar (tracks 2, 6) David Daniels—electric guitar (track 6) Oli Langford – violin (tracks 2, 6, 9–10, 12–13) Ian Burdge – cello (tracks 6, 8, 10, 12–13) Richie Mills – drums (tracks 6, 9) Arve Henriksen – trumpet (tracks 8, 13) Simon Heyworth – mastering
Sources: en.wikipedia.org
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.
Aqueous solutions are subject to oxidation and hydrolysis, so concentration and pH drift can occur even under refrigeration. Solid, dry material held cold and desiccated degrades far more slowly.
Mass spectrometry separates the parent from analogues that differ by a single modification, such as an amide versus acid terminus. Retention time alone is less reliable because closely related peptides can co-elute.
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.